# Nuclide record idea-alpha-first-mhspc (idea). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/ideas/idea-alpha-first-mhspc/>
  a schema:CreativeWork ;
  nuclide:kind "idea" ;
  schema:identifier "idea-alpha-first-mhspc" ;
  schema:name "Alpha-emitting PSMA therapy at first metastatic diagnosis"@en ;
  schema:description "If Pluvicto helps at first diagnosis, an alpha version might do more against microscopic disease, when tumour burden is smallest."@en ;
  schema:url <https://nuclide.cc/ideas/idea-alpha-first-mhspc/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04720157> ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/> ;
  nuclide:technologies <https://nuclide.cc/technologies/targeted-alpha-therapy/>, <https://nuclide.cc/technologies/radioligand-therapy/> ;
  nuclide:drugs <https://nuclide.cc/drugs/ac225-psma/>, <https://nuclide.cc/drugs/pluvicto/> ;
  nuclide:terms <https://nuclide.cc/terms/alpha-vs-beta/>, <https://nuclide.cc/terms/dosimetry/> ;
  nuclide:trials <https://nuclide.cc/trials/psmaddition/> .